PTC Therapeutics Raises Guidance on Strong Sephience Performance and Pipeline Momentum
Sephience Leads Revenue Growth: 36% Quarter-Over-Quarter Surge Powers Guidance Boost
PTC Therapeutics kicked off 2026 with revenue of $273 million for the first quarter, an increase of 47% in net product revenue compared to the same period last year. The standout was Sephience, which delivered $125 million in Q1 sales—up 36% from Q4 2025—as launch traction accelerated in the US and rolled out to new markets including Japan. The surge in patient starts, averaging about 140 new patients per month and surpassing 1,500 patients this quarter, fueled management’s decision to raise full-year product revenue guidance to a range of $750–$850 million.
| Key Product | Q1 2026 Revenue ($M) | Q1 2025 Revenue ($M) | QoQ Growth (%) |
|---|---|---|---|
| Sephience™ | 124.6 | N/A | 36 (vs Q4 '25) |
| Translarna™ | 59.0 | 86.2 | -32 |
| Emflaza® | 21.5 | 47.8 | -55 |
| Evrysdi® (Royalty) | 46.8 | 36.4 | 29 |
Pipeline Progress and Milestones: PIVOT-HD and INVEST-HD Move Forward
Beyond revenue, PTC spotlighted its R&D momentum: The 24-month interim analysis from the PIVOT-HD extension study showed a dose-dependent reduction in disease progression for votoplam in Huntington’s disease—slowing progression by 52% at the 10 mg dose compared to historical controls. The first patient in the global Phase 3 INVEST-HD study was dosed, triggering a $50 million milestone payment from Novartis. The vatiquinone program advanced as well, with an open-label study for Friedreich's ataxia slated for Q3 2026 after constructive discussions with the FDA.
Financials Reflect Growth and Ongoing Investment, Net Loss Driven by Lower Year-Over-Year Collaboration Revenue
Despite strong operating performance, PTC reported a net loss of $2.8 million for the quarter, compared to net income of $866.6 million in Q1 2025—a difference largely attributable to unusually high collaboration revenue in the prior year. Excluding non-cash, stock-based compensation, both R&D and SG&A expenses declined year over year, reflecting cost control as the company invests in its lead programs.
| Financial Metric | Q1 2026 ($M) | Q1 2025 ($M) |
|---|---|---|
| Total Revenue | 272.6 | 1,176.1 |
| Net Product Revenue | 225.6 | 153.4 |
| GAAP R&D Expense | 100.9 | 109.0 |
| Non-GAAP R&D Expense | 89.7 | 100.3 |
| GAAP SG&A Expense | 86.2 | 81.0 |
| Net (Loss) Income | -2.8 | 866.6 |
| Cash, Equivalents & Marketable Securities | 1,892.5 | 1,945.4 (end of 2025) |
Outlook: Raised Revenue Guidance and Pipeline Catalysts Ahead
Looking forward, PTC expects total 2026 product revenue of $750–$850 million and total revenue, including royalties, of $1.08–$1.18 billion. Pipeline developments—such as new data from ongoing trials, expanded launches of Sephience internationally, and regulatory steps for vatiquinone—are set to shape the next chapters for the company in 2026.
Investor Takeaway: Momentum Across Products and R&D Provides Multiple Catalysts
PTC Therapeutics combines strong commercial growth from Sephience and stable royalty streams from Evrysdi with meaningful pipeline progress. Investors should watch for updates on regulatory milestones and further geographic expansion of Sephience. The company’s cash reserves of nearly $1.9 billion provide a solid financial runway through its next wave of launches and clinical milestones.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI